IBRX270521C00008000
IBRX May 21 2027 8.00 Call
optionOPRA
InactiveSep 28, 2026
3.00USD+13.208%(+0.35)2Vol3OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
8
Expiration
May 21, 2027
DTE
213d
Moneyness
ITM
Intrinsic
$0.48
IBRX 8 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $2.17 | +3.33% | 11 | 23 |
| Oct 30, 2026 | 10d | $1.42 | -29.00% | 8 | 45 |
| Nov 6, 2026 | 17d | $1.85 | -31.23% | 10 | 507 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 20, 2026 | 31d | $1.75 | -28.57% | 129 | 1,315 |
| Nov 27, 2026 | 38d | $1.90 | -25.49% | 2 | 11 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Mar 19, 2027 | 150d | $3.00 | -11.76% | 59 | 1,300 |
| Apr 16, 2027 | 178d | $4.16 | +69.80% | 20 | 96 |
| May 21, 2027 | 213d | $3.00 | +13.21% | 2 | 3 |
IBRX Nearby Strikes · May 21, 2027
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.